Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | HTT | P42858 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639863 | 1.00 | KDM4E (1.00) | KDM4ERAB9ANPC1SMN1; SMN2CYP1A2 | |
| Phosphine SCHEMBL15543212 | 0.98 | KDM4E (0.97) | KDM4ERAB9ANPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL5334468 | 0.90 | RAB9A (0.82) | KDM4ERAB9ANPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL3639865 | 0.87 | KDM4E (0.77) | KDM4ERAB9ANPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL14922007 | 0.82 | KDM4E (0.69) | KDM4ERAB9ANPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL12325957 | 0.81 | KDM4E (0.68) | KDM4ERAB9ANPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL3668854 | 0.81 | RAB9A (0.68) | KDM4ERAB9ANPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL12325283 | 0.80 | KMT2A (1.00) | KDM4ERAB9ANPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL23024881 | 0.79 | RAB9A (0.66) | KDM4ERAB9ANPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL29475390 | 0.79 | KDM4E (0.74) | KDM4ERAB9ANPC1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843761-A | Method for preparing melanocortin analogue cyclic peptide drug based on hydrophobic label carrier | 浙江工业大学 | 2024-04-09 | — | — | CN | claimed |
| CN-117843715-A | Liquid phase synthesis method of melanoputan-II | 浙江工业大学 | 2024-04-09 | — | — | CN | claimed |
| CN-115093460-A | Method for synthesizing linaclotide intermediate and linaclotide in full liquid phase | 浙江工业大学 | 2022-09-23 | — | — | CN | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-3856164-B1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | ACHILLION PHARMACEUTICALS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-117843761-A | Method for preparing melanocortin analogue cyclic peptide drug based on hydrophobic label carrier | 浙江工业大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843715-A | Liquid phase synthesis method of melanoputan-II | 浙江工业大学 | 2024-04-09 | — | — | CN | disclosed |
| US-11807627-B2 | Morphic forms of complement factor D inhibitors | Achillon Pharmaceuticals, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-115884977-A | Stereoselective preparation of selected purine phosphoramidates | 阿堤亚制药公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-115093460-A | Method for synthesizing linaclotide intermediate and linaclotide in full liquid phase | 浙江工业大学 | 2022-09-23 | — | — | CN | disclosed |
| US-20220233673-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2022-07-28 | — | — | US | disclosed |
| EP-3980057-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | Institut Curie (FR) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | KDM4E 2432/4885RAB9A 1465/4885NPC1 4761/4885 |
| US-11807627-B2 | Morphic forms of complement factor D inhibitors | CFD, CFH, CFB | KDM4E 2408/4885RAB9A 1921/4885NPC1 1227/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | KDM4E 2972/4885RAB9A 1754/4885NPC1 4724/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | KDM4E 3678/4885RAB9A 1398/4885NPC1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.